Illumina to Develop NGS-based Oncology Companion Dx with AstraZeneca, Janssen Biotech, Sanofi | GenomeWeb

NEW YORK (GenomeWeb) — Illumina has partnered with AstraZeneca, Janssen Biotech, and Sanofi to develop a universal next-generation sequencing-based oncology test system for multi-analyte companion diagnostics, the company said today.

The goal of the partnership is to transition from single-analyte companion diagnostics to panel-based assays to select cancer therapies for patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.